Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
BCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.02 - $11.31
Previous CloseN/A
Volume537.69K
Average Volume (3M)3.06M
Market Cap
$1.74B
Enterprise Value$2.45B
Total Cash (Recent Filing)$295.09M
Total Debt (Recent Filing)$794.99M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Oct 29, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding209,920,430
10 Day Avg. Volume2,006,363
30 Day Avg. Volume3,063,616
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-3.27
Price to Sales (P/S)3.45
P/FCF Ratio-29.25
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue4.86
Enterprise Value/Gross Profit5.02
Enterprise Value/Ebitda55.90
Forecast
1Y Price Target
$17.50Price Target Upside110.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Market PenetrationOrladeyo market penetration is in line with expectations, indicating a strong and sustained launch.
Revenue GrowthIncreasing demand from patients with normal C1-inhibitor status supports continued revenue growth into the future.
Bears Say
European Market StrategyThe company announced the sale of their EU franchise, which no longer includes EU sales in peak sales models.
Regulatory ChallengesThe FDA extended the PDUFA for the Orladeyo granule formulation in pediatric HAE patients by 3 months, indicating potential regulatory delays.
BioCryst News
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $6.01 and its highest was $11.31 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is $1.74B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Oct 29, 2025 which is in 58 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Aug 04, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.007 by $0.013.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is 0.03.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 209,920,430 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of $0.02 in its last earnings report, beating expectations of $0.007. Following the earnings report the stock price went up 9.811%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
BioCryst Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.50 (110.59% Upside)
$17.50 (110.59% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 60%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 226.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $595.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.70%
12-Months-Change
Fundamentals
Return on Equity
18.68%
Trailing 12-Months
Asset Growth
-3.22%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly those related to genetic disorders and viral infections. The company's core products include Orladeyo (berotralstat), an oral medication approved for the prevention of hereditary angioedema attacks, and other pipeline candidates aimed at treating conditions such as COVID-19 and various forms of cancer. BioCryst operates primarily in the pharmaceutical sector, leveraging its proprietary drug development technologies to address unmet medical needs.
BCRX Company Deck
BCRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record-breaking ORLADEYO performance, strong financial management, and strategic advancements in the pipeline. The successful sale of the European business and leadership transition further strengthened the company's position. While there are potential challenges with new market entrants and a delay in the pediatric ORLADEYO approval, the positive aspects of the call significantly outweigh the lowlights.View all BCRX earnings summariesBCRX Stock 12 Month Forecast
Average Price Target
$17.50
▲(110.59% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
MannKind
―
Agios Pharma
―
Disc Medicine
―
Kymera Therapeutics
―
Ownership Overview
1.77% Insiders
17.53% Mutual Funds
28.77% Other Institutional Investors
34.78% Public Companies and
Individual Investors